Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
NOVO-NORDISK AS (NVO)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-05
$40.30-4.46%
Close 2026-11-05 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
22.12 → 22.10 EPS · FY ending Dec 31, 2027 · 7 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 7 to 7; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for NVO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage competitive pressure from Eli Lilly and patent expirations | A supporting condition in NOVO-NORDISK AS's published investment case. The stated target is No material loss of market share or revenue due to competition in FY26. | Intact | Significant market share loss or revenue decline from competition or patent expiry | Guidance -2% to +2% vs no material loss Novo Nordisk guided for -2% to +2% 2026 growth and raised outlook, with Wegovy hitting 80% milestone and beating forecasts. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is best described as a company-specific thesis with a supportive sector tailwind, but the evidence does not establish a clear business category or long-term direction. The thesis state is insufficient because there is not enough recent financial-performance history to assess it.
The evidence shows low fragility, meaning no listed warning signs suggest the current thesis is especially vulnerable. It does not provide enough valuation or expectations data to say whether NVO is cheap, fair, or expensive versus peers, or what the market already assumes.
Near term, the stated chance of an earnings miss is low, though the evidence notes a deep miss in recent history and a downward trend in earnings surprises. The Healthcare backdrop has strengthened, but the evidence gives no recent company-level results or management execution details to support a clear multi-year fundamentals trajectory.
Near-term sector support depends partly on whether Healthcare bellwethers LLY, JNJ, and ABBV continue to report strong results and raise guidance. A weakening jobs trend could increase recession concerns, while weaker results or guidance from those bellwethers could reduce the sector tailwind; the evidence does not show how these factors affect NVO’s own business.
For the next 1 to 3 years, the evidence supports a cautious and low-confidence read: sector conditions have improved, but the company-specific thesis remains insufficiently established. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
EPS at or above $21.6 in FY26 | A primary condition in NOVO-NORDISK AS's published investment case. The stated target is >= $21.6. | Under Pressure | EPS falls below $20 in FY26 | Diluted EPS: DKK 4.74 per share FY2026-Q2; GAAP. Published target: >= $21.6. Annual target cannot be compared with a quarterly or TTM observation. Aug 4, 20264.74 DKK/share · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Successful launch and market expansion of Wegovy and obesity treatments | New product launches and partnerships support growth. | Intact | Failure to gain regulatory approval or market traction for Wegovy in China | Wegovy 80% milestone vs China approval target Wegovy adoption milestone and pill outperformance confirm strong demand. Earnings miss noted but does not break the China-specific trip condition. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Total revenue at or above $293 billion in FY26 | A primary condition in NOVO-NORDISK AS's published investment case. The stated target is >= $293 billion. | Under Pressure | total revenue falls below $270 billion in FY26 | Revenue: DKK 78.488B FY2026-Q2; GAAP. Published target: >= $293 billion. Annual target cannot be compared with a quarterly or TTM observation. Aug 4, 202678,488,000,000 DKK · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$21.43 → $22.10 · observed estimates
$297.96B → $309.60B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $21.43 | $297,962,479,466 | 7 / 15 |
| 2026-07-25 | $21.43 | $297,962,479,466 | 7 / 15 |
| 2026-07-26 | $21.44 | $298,255,072,702 | 7 / 16 |
| 2026-07-27 | $21.44 | $298,255,072,702 | 7 / 16 |
| 2026-07-28 | $21.39 | $300,213,387,560 | 8 / 27 |
| 2026-07-29 | $21.39 | $300,213,387,560 | 8 / 27 |
| 2026-07-30 | $21.39 | $300,213,387,560 | 8 / 27 |
| 2026-07-31 | $21.39 | $300,121,979,390 | 8 / 26 |
| 2026-08-01 | $21.44 | $298,228,150,526 | 7 / 16 |
| 2026-08-02 | $21.25 | $300,115,249,200 | 9 / 27 |
| 2026-08-03 | $21.25 | $300,115,249,200 | 9 / 27 |
| 2026-08-04 | $21.44 | $298,148,906,248 | 7 / 15 |
| 2026-08-05 | $21.44 | $298,148,906,248 | 7 / 15 |
| 2026-08-06 | $21.44 | $298,148,906,248 | 7 / 15 |
| 2026-08-07 | $21.73 | $301,832,502,425 | 8 / 16 |
| 2026-08-08 | $21.61 | $303,466,194,610 | 8 / 26 |
| 2026-08-09 | $21.64 | $303,677,734,720 | 8 / 26 |
| 2026-08-10 | $21.73 | $301,832,502,425 | 8 / 16 |
| 2026-08-12 | $21.73 | $304,526,084,370 | 8 / 26 |
| 2026-08-13 | $21.73 | $301,832,502,425 | 8 / 16 |
| 2026-08-14 | $21.73 | $301,832,502,425 | 8 / 16 |
| 2026-08-15 | $21.73 | $301,832,502,425 | 7 / 15 |
| 2026-08-16 | $21.73 | $301,832,502,425 | 7 / 15 |
| 2026-08-17 | $21.73 | $301,832,502,425 | 7 / 15 |
| 2026-08-18 | $21.73 | $301,832,502,425 | 7 / 16 |
| 2026-08-19 | $21.73 | $301,832,502,425 | 7 / 16 |
| 2026-08-20 | $21.80 | $303,665,415,103 | 7 / 16 |
| 2026-08-21 | $21.80 | $303,665,415,103 | 7 / 16 |
| 2026-08-22 | $21.80 | $303,665,415,103 | 7 / 16 |
| 2026-08-23 | $21.80 | $303,665,415,103 | 7 / 16 |
| 2026-08-24 | $21.80 | $303,665,415,103 | 7 / 16 |
| 2026-08-25 | $21.86 | $304,375,697,155 | 7 / 16 |
| 2026-08-26 | $21.91 | $304,527,247,608 | 7 / 16 |
| 2026-08-27 | $21.91 | $304,527,247,608 | 7 / 16 |
| 2026-08-28 | $21.91 | $304,527,247,608 | 7 / 16 |
| 2026-08-29 | $21.92 | $304,704,776,201 | 7 / 16 |
| 2026-08-30 | $21.75 | $304,704,776,201 | 7 / 16 |
| 2026-08-31 | $21.75 | $304,704,776,201 | 7 / 16 |
| 2026-09-01 | $21.78 | $305,199,007,343 | 7 / 16 |
| 2026-09-02 | $21.78 | $305,275,326,091 | 7 / 16 |
| 2026-09-03 | $21.78 | $305,594,532,841 | 7 / 16 |
| 2026-09-04 | $21.78 | $305,594,532,841 | 7 / 16 |
| 2026-09-05 | $21.78 | $305,602,282,397 | 7 / 16 |
| 2026-09-06 | $21.78 | $305,599,260,054 | 7 / 16 |
| 2026-09-07 | $21.78 | $305,599,260,054 | 7 / 16 |
| 2026-09-08 | $21.78 | $305,599,260,054 | 7 / 16 |
| 2026-09-09 | $21.80 | $305,599,260,054 | 7 / 16 |
| 2026-09-10 | $21.82 | $305,933,602,076 | 7 / 16 |
| 2026-09-11 | $21.82 | $305,959,783,289 | 7 / 16 |
| 2026-09-12 | $21.81 | $306,043,959,998 | 7 / 16 |
| 2026-09-13 | $21.83 | $306,227,951,311 | 7 / 16 |
| 2026-09-14 | $21.83 | $306,227,951,311 | 7 / 16 |
| 2026-09-15 | $21.84 | $306,296,196,961 | 7 / 16 |
| 2026-09-16 | $21.82 | $306,168,636,366 | 7 / 16 |
| 2026-09-17 | $21.82 | $306,213,288,590 | 7 / 16 |
| 2026-09-18 | $21.82 | $306,213,288,590 | 7 / 16 |
| 2026-09-19 | $21.82 | $306,213,288,590 | 7 / 16 |
| 2026-09-20 | $21.98 | $306,911,822,341 | 7 / 16 |
| 2026-09-21 | $21.89 | $305,643,962,150 | 7 / 16 |
| 2026-09-22 | $21.92 | $306,069,711,574 | 7 / 16 |
| 2026-09-23 | $21.94 | $305,148,989,009 | 7 / 16 |
| 2026-09-24 | $21.94 | $305,148,989,009 | 7 / 16 |
| 2026-09-25 | $21.98 | $306,226,101,016 | 7 / 16 |
| 2026-09-26 | $21.98 | $306,272,580,925 | 7 / 16 |
| 2026-09-27 | $21.98 | $306,272,580,925 | 7 / 16 |
| 2026-09-28 | $22.05 | $307,296,728,782 | 7 / 16 |
| 2026-09-29 | $22.07 | $307,617,505,620 | 7 / 16 |
| 2026-09-30 | $22.07 | $307,617,505,620 | 7 / 16 |
| 2026-10-01 | $22.11 | $308,222,799,134 | 7 / 16 |
| 2026-10-02 | $22.15 | $308,822,379,235 | 7 / 16 |
| 2026-10-03 | $22.13 | $308,471,421,084 | 7 / 16 |
| 2026-10-04 | $22.13 | $308,471,421,084 | 7 / 16 |
| 2026-10-05 | $22.17 | $309,088,635,036 | 7 / 16 |
| 2026-10-06 | $22.12 | $308,364,023,545 | 7 / 16 |
| 2026-10-07 | $22.10 | $308,039,882,904 | 7 / 16 |
| 2026-10-08 | $22.08 | $307,823,982,269 | 7 / 16 |
| 2026-10-09 | $22.07 | $307,760,852,544 | 7 / 16 |
| 2026-10-10 | $22.07 | $307,760,852,544 | 7 / 16 |
| 2026-10-11 | $22.07 | $307,706,077,636 | 7 / 16 |
| 2026-10-12 | $22.10 | $308,174,898,915 | 7 / 16 |
| 2026-10-13 | $22.18 | $308,757,820,011 | 7 / 16 |
| 2026-10-14 | $22.23 | $309,486,209,520 | 7 / 15 |
| 2026-10-15 | $22.23 | $309,597,684,404 | 7 / 15 |
| 2026-10-16 | $22.30 | $310,477,774,661 | 7 / 15 |
| 2026-10-17 | $22.30 | $310,477,774,661 | 7 / 15 |
| 2026-10-18 | $22.27 | $310,155,367,062 | 7 / 15 |
| 2026-10-19 | $22.27 | $310,154,537,014 | 7 / 15 |
| 2026-10-20 | $22.20 | $309,846,026,193 | 7 / 15 |
| 2026-10-21 | $22.26 | $311,034,404,566 | 7 / 15 |
| 2026-10-22 | $22.26 | $311,034,404,566 | 7 / 15 |
| 2026-10-23 | $22.28 | $311,298,452,392 | 7 / 15 |
| 2026-10-24 | $22.18 | $310,870,596,206 | 7 / 15 |
| 2026-10-25 | $22.18 | $310,870,596,206 | 7 / 15 |
| 2026-10-26 | $22.18 | $310,870,596,206 | 7 / 15 |
| 2026-10-27 | $22.18 | $310,870,596,206 | 7 / 15 |
| 2026-10-28 | $22.16 | $310,670,207,622 | 7 / 15 |
| 2026-10-29 | $22.16 | $310,670,207,622 | 7 / 15 |
| 2026-10-30 | $22.14 | $310,368,145,836 | 7 / 15 |
| 2026-10-31 | $22.10 | $309,595,508,035 | 7 / 15 |
| 2026-11-01 | $22.10 | $309,595,508,035 | 7 / 15 |
| 2026-11-02 | $22.10 | $309,595,508,035 | 7 / 15 |
| 2026-11-03 | $22.10 | $309,595,525,311 | 7 / 15 |
| 2026-11-04 | $22.10 | $309,595,525,311 | 7 / 15 |
| 2026-11-05 | $22.10 | $309,595,525,311 | 7 / 15 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 10 Hold · 1 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 1 recorded
0 raises · 1 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.